Engineered Antibodies to Improve Brain Delivery of Oligonucleotide
- Antibody-based "brain shuttles" can deliver therapeutic oligonucleotides to the brain, but the biophysical properties of payload can negatively affect pharmacokinetics
- Engineered antibody complexes with additional binders are used to mask the payload
- These engineered entities demonstrate improved specific targeting in cellular models, and improved PK and brain delivery in animal models